Follow
Translational Oncology
Translational Oncology involves moving scientific discoveries made in a laboratory setting into clinical applications that enhance treatment efficacy and outcomes for cancer patients. Translational Oncology approaches include pre-clinical research, which can be done in an in vivo, in vitro, or ex vivo setting, before validating the laboratory findings with a clinical trial.
-
FEB 24, 2021 | 12:00 PM
With an introduction by Sarah Warren, the Senior Director of Translational Science, this webinar will open by providing a brief technology overview of NanoString Technologies. Dr. Warren wil...Speaker: Jason Frazier , Sarah Warren, PhDPresented at: Drug Discovery & Development Virtual Event Series 2021
Sponsored By: NanoString TechnologiesFEB 24, 2021 | 7:30 AM
Specific biomarker assays are included in an increasing number of drug labels, with uses ranging from prediction of adverse events to providing insights on efficacy for patient populations....Speaker: Steven M. Anderson, PhDPresented at: Drug Discovery & Development Virtual Event Series 2021
FEB 24, 2021 | 12:00 AM
The development of different classes of immunotherapies that target cancer cells continues to be a rapidly growing area of research. The development of diagnostic tests which can predict pat...FEB 03, 2021 | 8:00 AM
Date: February 3, 2021 Time: 8:00am (PST), 11:00am (EST) This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field...JAN 12, 2021 | 8:00 AM
DATE: January 12, 2021 TIME: 8:00 am PST, 11:00 am EST, 5:00pm CET Transferring a biologic candidate from the research and development phase to commercial production usually requires increas...DEC 07, 2020 | 9:00 AM
Date: December 7, 2020 Time: 9:00am (PST), 12:00pm (EST) The simultaneous detection of biomarkers on tissue samples plays a fundamental role in the study of the tumor microenvironment. Multi...DEC 03, 2020 | 10:30 AM
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 20...Speaker: Arutha Kulasinghe, PhD , Miguel Muñoz-Ruiz, PhDDEC 02, 2020 | 8:00 AM
DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...NOV 12, 2020 | 3:00 PM
What if your lab could perform exome sequencing with the same sensitivity and efficiency of targeted sequencing? The new integrated QIAseq Human Exome TR Insights solution from QIAGEN delive...Speaker: Brian Dugan, M.S. , Rupert Yip, PhDNOV 12, 2020 | 9:00 AM
Testing volumes need to increase by orders of magnitude in order to restore communities back to normality. This workshop focuses on solutions that equip laboratories to participate in expand...Speaker: Dr. Jared R. Auclair , Frank Ong, MD, CPI, CCRPPresented at: Clinical Diagnostics & Research Virtual Event Series 2020
Sponsored By: Thermo Fisher ScientificNOV 12, 2020 | 12:00 AM
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...OCT 22, 2020 | 1:35 PM
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...OCT 22, 2020 | 1:35 PM
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...OCT 22, 2020 | 12:25 PM
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...Speaker: Megan S. Lim, MD, PhDPresented at: OncomineWorld Autumn: A virtual NGS education meeting
OCT 22, 2020 | 12:25 PM
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...OCT 22, 2020 | 6:35 AM
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...OCT 22, 2020 | 6:35 AM
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...OCT 22, 2020 | 6:05 AM
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...OCT 22, 2020 | 6:05 AM
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...OCT 21, 2020 | 9:05 PM
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...OCT 21, 2020 | 9:05 PM
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...OCT 15, 2020 | 9:00 AM
Date: October 15, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Renal transporters play an important role in potential clinical drug-drug interactions (DDIs) as highlighted in the FDA, EMA and PMDA...OCT 13, 2020 | 2:30 PM
...Speaker: Arjun Khanna , David Chi Leung Lam, MD, PhD , Chein-Feng Li, MD , Darren Wan Teck LimOCT 08, 2020 | 10:00 AM
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
FEB 24, 2021 | 12:00 PM
With an introduction by Sarah Warren, the Senior Director of Translational Science, this webinar will open by providing a brief technology overview of NanoString Technologies. Dr. Warren wil...
Speaker:
Jason Frazier
, Sarah Warren, PhD
Presented at: Drug Discovery & Development Virtual Event Series 2021
Sponsored By: NanoString Technologies
Sponsored By: NanoString Technologies
FEB 24, 2021 | 7:30 AM
Specific biomarker assays are included in an increasing number of drug labels, with uses ranging from prediction of adverse events to providing insights on efficacy for patient populations....
Speaker:
Steven M. Anderson, PhD
Presented at: Drug Discovery & Development Virtual Event Series 2021
FEB 24, 2021 | 12:00 AM
The development of different classes of immunotherapies that target cancer cells continues to be a rapidly growing area of research. The development of diagnostic tests which can predict pat...
FEB 03, 2021 | 8:00 AM
Date: February 3, 2021 Time: 8:00am (PST), 11:00am (EST) This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field...
JAN 12, 2021 | 8:00 AM
DATE: January 12, 2021 TIME: 8:00 am PST, 11:00 am EST, 5:00pm CET Transferring a biologic candidate from the research and development phase to commercial production usually requires increas...
DEC 07, 2020 | 9:00 AM
Date: December 7, 2020 Time: 9:00am (PST), 12:00pm (EST) The simultaneous detection of biomarkers on tissue samples plays a fundamental role in the study of the tumor microenvironment. Multi...
DEC 03, 2020 | 10:30 AM
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and has spread globally, causing a pandemic of respiratory illness designated coronavirus disease 20...
Speaker:
Arutha Kulasinghe, PhD
, Miguel Muñoz-Ruiz, PhD
DEC 02, 2020 | 8:00 AM
DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
NOV 12, 2020 | 3:00 PM
What if your lab could perform exome sequencing with the same sensitivity and efficiency of targeted sequencing? The new integrated QIAseq Human Exome TR Insights solution from QIAGEN delive...
Speaker:
Brian Dugan, M.S.
, Rupert Yip, PhD
NOV 12, 2020 | 9:00 AM
Testing volumes need to increase by orders of magnitude in order to restore communities back to normality. This workshop focuses on solutions that equip laboratories to participate in expand...
Speaker:
Dr. Jared R. Auclair
, Frank Ong, MD, CPI, CCRP
Presented at: Clinical Diagnostics & Research Virtual Event Series 2020
Sponsored By: Thermo Fisher Scientific
Sponsored By: Thermo Fisher Scientific
NOV 12, 2020 | 12:00 AM
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
OCT 22, 2020 | 1:35 PM
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
OCT 22, 2020 | 1:35 PM
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
OCT 22, 2020 | 12:25 PM
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
Speaker:
Megan S. Lim, MD, PhD
Presented at: OncomineWorld Autumn: A virtual NGS education meeting
OCT 22, 2020 | 12:25 PM
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
OCT 22, 2020 | 6:35 AM
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...
OCT 22, 2020 | 6:35 AM
Myeloid neoplasms are a group of heterogeneus disorders originating from the neoplastic transformation of a pluripotent hematopoietic progenitor cell. Following the acquisition of somatic mu...
OCT 22, 2020 | 6:05 AM
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
OCT 22, 2020 | 6:05 AM
Precision oncology is revolutionizing the diagnostic and therapeutic approach to cancer. In fact, the availability of tumor-specific and tumor-agnostic biomarkers and matched therapies is ra...
OCT 21, 2020 | 9:05 PM
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
OCT 21, 2020 | 9:05 PM
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
OCT 15, 2020 | 9:00 AM
Date: October 15, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Renal transporters play an important role in potential clinical drug-drug interactions (DDIs) as highlighted in the FDA, EMA and PMDA...
OCT 13, 2020 | 2:30 PM
...
Speaker:
Arjun Khanna
, David Chi Leung Lam, MD, PhD
, Chein-Feng Li, MD
, Darren Wan Teck Lim
OCT 08, 2020 | 10:00 AM
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...